Isoxazol-5(4H)one derivatives as PTP1B inhibitors showing an anti-obesity effect. 2011

Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
Department of Chemistry, Inha University, 253 Yonghyun-dong, Nam-gu, Incheon 402-751, Korea.

In developing inhibitors of therapeutic target enzymes, significant time and effort are committed to the preparation of large numbers of compounds. In an effort to develop a potent inhibitor of protein tyrosine phosphatase (PTP) 1B as an anti-obesity and/or anti-diabetic agent, we constructed an isoxazolone chemical library by using a simplified procedure that circumvents tedious workup and purification steps. The 10×7 isoxazolone derivatives were synthesized by coupling the two halves of the target compounds. When mixed and heated in test tubes, the precursors produced the reaction products as precipitates. After brief washing, the products were pure enough to be used for enzymatic experiments. With the precursors for the coupling reactions prepared, the 10×7 library compounds could be prepared in a day by using the present protocol. The library compounds thus obtained were examined for their inhibitory activities against PTP1B. Among them, compound C3 was the most potent inhibitor of PTP1B with an IC(50) of 2.3 μM. The in vivo effect of C3 was also examined in an obesity-prone mouse strain. Diet-induced obese (DIO)/diabetic mice were divided into two groups and each group was fed a high-fat diet (HFD) or HFD+C3 for four weeks. The group of C3-fed mice gained significantly less weight relative to the HFD-fed control group during the four weeks of the drug feeding period. In contrast to the anti-obesity effect of C3, no difference was observed in the glycemic control of the HFD and HFD+C3 mice groups.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054562 Protein Tyrosine Phosphatase, Non-Receptor Type 1 A subtype of non-receptor protein tyrosine phosphatases that includes two distinctive targeting motifs; an N-terminal motif specific for the INSULIN RECEPTOR, and a C-terminal motif specific for the SH3 domain containing proteins. This subtype includes a hydrophobic domain which localizes it to the ENDOPLASMIC RETICULUM. PTPase 1B,PTPase HA2,Protein Tyrosine Phosphatase 1B,Protein-Tyrosine Phosphatase HA2,Protein Tyrosine Phosphatase HA2,Protein Tyrosine Phosphatase, Non Receptor Type 1
D019440 Anti-Obesity Agents Agents that increase energy expenditure and weight loss by neural and metabolic regulation. Anti-Obesity Agent,Anti-Obesity Drug,Antiobesity Agent,Antiobesity Drug,Weight-Loss Agents,Weight-Loss Drug,Anti-Obesity Drugs,Antiobesity Agents,Antiobesity Drugs,Weight-Loss Drugs,Agent, Anti-Obesity,Agent, Antiobesity,Agents, Anti-Obesity,Agents, Antiobesity,Agents, Weight-Loss,Anti Obesity Agent,Anti Obesity Agents,Anti Obesity Drug,Anti Obesity Drugs,Drug, Anti-Obesity,Drug, Antiobesity,Drug, Weight-Loss,Drugs, Anti-Obesity,Drugs, Antiobesity,Drugs, Weight-Loss,Weight Loss Agents,Weight Loss Drug,Weight Loss Drugs

Related Publications

Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
October 2007, Bioorganic & medicinal chemistry,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
November 2015, Chemical biology & drug design,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
November 2012, Acta crystallographica. Section E, Structure reports online,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
November 2009, Acta crystallographica. Section E, Structure reports online,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
November 2010, Bioorganic & medicinal chemistry letters,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
April 2014, Journal of medicinal chemistry,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
November 2009, Acta crystallographica. Section E, Structure reports online,
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
April 2024, Medicinal chemistry (Shariqah (United Arab Emirates)),
Bhooshan Kafle, and Nilkanth G Aher, and Deegendra Khadka, and Hwangseo Park, and Hyeongjin Cho
October 2018, Acta pharmaceutica Sinica. B,
Copied contents to your clipboard!